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Abstract:  
Background: The clinical trial design for primary progressive multiple sclerosis (PPMS) 
requires understanding of disability progression in modern patient cohorts. 
Objective: To characterize demographic and clinical characteristics of the CLIMB study 
(Boston, MA) PPMS patient cohort and assess rate of disability progression.  
Methods: We studied PPMS (n = 73) and relapsing-onset MS (ROMS) patients (n = 
1541) enrolled in CLIMB, a longitudinal study of MS patients at the Brigham and 
Women’s Hospital (Boston, MA). Disability progression for each group was compared 
using interval-censored survival analysis and time to six-month sustained progression.   
Results: The PP group had 1.09:1 male:female ratio compared to 1:2.89 for the RO 
group and greater mean age of onset (PP: 44.4+/-9.6; RO: 32.7+/-9.9; p<0.0001). Motor 
symptoms at onset and first symptoms localized to spinal cord were each strongly 
associated with PPMS (p<0.001). Median time from onset to EDSS 6.0 was faster in 
PPMS (p<0.001). PPMS patients progressed faster to EDSS 3 (p<0.001) and from 
EDSS 3 to 6 (p<0.001). Median time to sustained progression in the PP group was 4.85 
years (95% CI 2.83-8.35), significantly faster than the RO group (p<0.001). 
Conclusions: Our modern PPMS cohort is demographically similar to previously 
studied cohorts. PPMS is associated with faster disability accrual than ROMS. Current 
real-world observations of time to sustained progression will inform design of new 
clinical trials for PPMS. 
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Glossary: 
CLIMB “Comprehensive Longitudinal Investigation of Multiple Sclerosis at 
the Brigham and Women’s Hospital” 
EDSS Expanded Disability Status Scale 
MS Multiple sclerosis 
MSSS Multiple Sclerosis Severity Score 
PP Primary progressive 
PR Progressive-relapsing 
RO Relapsing-onset 
RR Relapsing remitting 
SP Secondary progressive 
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Introduction: 
Multiple sclerosis (MS), the most common cause of neurological disability among 
young adults in the Western world, is a disease with significant heterogeneity in 
presentation and characterized by inflammation and chronic degeneration in the central 
nervous system (CNS).(1) Combinations and permutations of the two fundamental 
clinical phenomena of MS, acute relapse and persistent disease progression 
(permanent disability accrual), result in varied clinical course patterns that form the main 
clinical subtypes of MS (2): relapsing-remitting (RRMS), secondary progressive 
(SPMS), primary progressive (PPMS), and progressive-relapsing (PRMS). 
A majority of MS patients begin with RRMS, characterized by distinct disease 
relapses with full recovery or some residual deficit upon recovery and progression-free 
periods between relapses.(3) 2-3% of RRMS patients annually convert to SPMS (4), 
which is characterized by progression in the presence or absence of relapses, 
remissions, and plateaus.(3) Because RR and SPMS share the same relapsing-
remitting presentation at disease onset, they are together referred to as relapsing-onset 
MS (ROMS). PPMS is found in approximately 10-15% of the MS population, has the 
worst prognosis of MS subtypes, and is characterized by continued worsening of 
disease from onset with occasional minor improvements or plateaus.(3, 5) PRMS, which 
presents as progressive disease from onset with superimposed distinct relapses, is 
quite rare and is frequently considered to share a similar natural history to PPMS.(4, 6)  
Despite the broad spectrum of clinical manifestations, it is generally accepted 
that MS subtypes derive from common disease mechanisms. Supporting this notion, a 
multicenter genome-wide association study found numerous genetic associations with 
MS as a whole but no differences in genetic associations based on the clinical subtype 
of MS.(7) 
The average age of disease onset for ROMS is ~30 years while ~40 years is the 
mean age of onset for PPMS and SPMS progression.(2, 3) In large natural history 
studies, the SP and PP patients both tend to have lower extremity motor symptoms at 
onset of progression and rates of disease progression are similar, though SP patients 
do accumulate disability a bit faster.(4, 6) These reports have also shown that the age 
at higher disability thresholds is similar between RO and PP patients.(6, 8) From a 
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statistical and population based standpoint, these findings suggest that MS disease 
course and prognosis may simply be age-dependent and that a unique variation on 
inflammatory processes underlies the development of progressive disease.(4, 6) 
Though MS is generally accepted today as a single disease with significant 
heterogeneity, from a clinical standpoint RO and PPMS are distinct entities. The 
dissimilarities between PP and RRMS suggest important pathophysiologic differences. 
On the other hand, PP and SPMS share many similarities, raising the possibility of 
similar pathophysiology leading to any form of progressive disease. Indeed, the acute 
relapse is dependent on significant inflammatory episodes while progressive disease is 
more a result of neurodegeneration.(2, 3) It is important to understand the unique 
nuances of the MS subtypes in order to develop effective therapies and provide the best 
patient care possible.  
PPMS is a topic of particular interest as no effective therapy for PPMS is 
currently available.(5, 9, 10) PPMS is characterized by high neurodegenerative impact 
and the lowest inflammatory impact on disability.(3) Though there are focal white matter 
plaques, the number of classical active white matter lesions is low. Instead, there is 
extensive demyelination of the cerebral cortex and diffuse axonal injury in the normal-
appearing white matter in the setting of a global, mild inflammatory state.(11) Overall, 
PPMS pathology reflects a classical inflammatory disease in which persistent 
inflammation is associated with axonal injury.(12) 
Magnetic resonance imaging (MRI) findings are compatible with the pathological 
observations in PPMS. PPMS has a smaller lesion load and fewer gadolinium-
enhancing lesions compared with ROMS, though the lesions still appear in classic 
periventricular, juxtacortical, and infratentorial locations. About half of PPMS patients 
have evidence of diffuse mild hyperintensity on T2-weighted imaging, reflecting the low 
level global CNS inflammation. Furthermore, cortical demyelination and 
neurodegeneration are reflected as diffusion abnormalities in healthy appearing grey 
and white matter and progressive atrophy that is most pronounced in the deep grey 
matter.(3) Notably, cervical cord atrophy is associated with disability and only seen in 
PPMS.(13) 
Interestingly, MRI changes are known to occur at least 10 years prior to clinical 
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presentation of PPMS. This suggests that there may be a subclinical period of 
inflammation and disease activity preceding clinical progressive disease until a specific 
threshold of neurodegenerative damage is reached.(14) 
The majority (80%) of PPMS patients present with progressive spastic 
paraparesis, typically in the lower extremities.(3) Unfortunately, despite the recent 
proliferation of immunomodulatory treatments targeting RRMS that have been approved 
by the FDA, no effective therapy for PPMS is currently available although some trials for 
progressive disease are ongoing.(5, 9, 10) Careful study of PPMS demographic 
characteristics and disease progression, clinically evaluated by disability accumulation 
based on the Expanded Disability Status Scale score (EDSS, scale ranges 1-10, 
Appendix A) (15), is important to improve patient diagnosis and care and to help design 
randomized clinical trials targeting the PPMS population.(16) 
Though natural history studies of PPMS have been conducted (17), it is difficult 
to study large cohorts and accurately portray the course of PPMS as PPMS is only a 
small subgroup of the total MS population. In addition, many of the past studies 
characterizing PPMS or progressive-onset patients may have included patients 
diagnosed with PPMS prior to the introduction of stringent McDonald diagnostic 
criteria.(18, 19) As well, patients often did not present to the clinic early in the disease 
course.(20) Overall rates of disease progression are not clear, especially given recent 
data suggesting these may be changing with time or geographical location.(21, 22) The 
need for better estimates of the rate of disease progression in PPMS was highlighted 
when a recent clinical trial for glatiramer acetate in PPMS was terminated because 
short-term disease progression, measured by disability accumulation, was slower than 
anticipated (23) based on prior studies. 
Two recent studies from large French cohorts suggested that MS disability 
accumulation consists of two independent phases, with Phase 1 being the duration from 
disease onset to EDSS=3 or =4 and Phase 2 being the duration from EDSS =3 or =4 to 
EDSS=6.(6, 24, 25) Progression through Phase 1 was highly variable while median 
Phase 2 progression seemed consistent in length from 6-9 years regardless of Phase 1 
length.(25) The influence of risk factors also differed between the phases.(24, 25) 
However, this two-stage model has been sparsely validated in well-defined PPMS 
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patient populations. 
Few studies have focused on PPMS disease progression, particularly in a 
modern cohort with widespread use of immunomodulatory therapies. For this study, the 
rate of disability progression in PPMS was investigated in a well-characterized, modern 
cohort that is longitudinally and prospectively followed at the Partners Multiple Sclerosis 
Center in Boston, MA as part of the “Comprehensive Longitudinal Investigation of 
Multiple Sclerosis at the Brigham and Women’s Hospital” (CLIMB study). Furthermore, 
the time to six-month sustained progression, a measure that may be useful for future 
clinical trial design, was estimated and used to generate sample size calculations for 
hypothetical PPMS trials. 
 
A report of this work has been previously published and the complete citation is found in 
the references section.(26)  
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Methods: 
Subjects 
The CLIMB is a longitudinal prospective study, established in 2000, of MS 
patients followed at the Partners MS Center, Brigham and Women’s Hospital.(27) All 
patients seen at the Partners MS Center are offered enrollment in CLIMB. More than 
80% of the active (clinical visit in past year) patients seen at this Center are enrolled in 
the CLIMB study. Inclusion criteria for the CLIMB study are: 1) diagnosis of MS or 
clinically isolated syndrome (CIS); 2) willingness to participate in a longitudinal study 
with biannual clinical visits and annual blood draws; 3) ability to complete annual MRI at 
the Brigham or equivalent facility. Patients are seen every six months and have detailed 
demographic, clinical, immunological, and MRI data validated and prospectively 
recorded in an Oracle-based electronic relational database. MS diagnosis is made by 
an expert neurologist based on the McDonald diagnostic criteria and available 
subjective and objective data.(18, 19) Patients in the CLIMB study with a definite 
diagnosis of MS were included in our query on November 11, 2012. To ensure use of 
up-to-date diagnostic criteria, patients with a most recent visit prior to 2010 were not 
included in the study. The CLIMB patients were classified as either PPMS or ROMS, 
which includes RRMS and SPMS, based on the physician diagnosis. Of the 73 PPMS 
patients, 70 (96%) fulfilled the McDonald 2010 criteria for PPMS. Two patients did not 
meet criteria due to a lack of data: no cord imaging or cerebrospinal fluid (CSF) studies 
within our system. One patient had normal spine MRI and CSF analysis but was felt to 
have PPMS because of the clinical presentation and abnormal brain MRI.  One patient 
initially diagnosed with PPMS was found to have PRMS and was excluded from the PP 
cohort. Demographic characteristics of the PPMS and ROMS groups are presented in 
Table 1. To ensure that CLIMB PPMS patients were a representative sample of PPMS 
patients seen at the Partners MS Center, demographic characteristics of CLIMB PPMS 
patients are compared to non-CLIMB PPMS patients in Table 2. 
 
Clinical markers and measures 
The time to two main landmark EDSS values were investigated: EDSS=3 and 
EDSS=6. Based on previous work, the time from disease onset to EDSS=3 was defined 
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as Phase 1, and the time from EDSS=3 to EDSS=6 was defined as Phase 2.(25) Given 
the varied disease duration among the patients, the Multiple Sclerosis Severity Score 
(MSSS), which combines the EDSS and disease duration, was also calculated for the 
last visit.(28) 
In addition to specific EDSS landmarks, time to sustained disease progression 
was also investigated. Sustained progression was defined as an increase of at least 1.5 
points on the EDSS for patients with a baseline EDSS=0, an increase of at least one 
point on the EDSS for patients with initial EDSS scores between 1 and 5 or an increase 
of 0.5 points for patients with initial EDSS scores of 5.5 or greater that were 
subsequently maintained or increased for at least 180 days. The date of sustained 
progression was defined as the visit date at which sustained progression began.  
 
Statistical Analysis 
Demographic characteristics, type of first symptom, and first symptom lesion 
localization were compared between the PPMS patients and the ROMS patients using 
Fisher’s exact test and Wilcoxon rank sum test as appropriate. The same tests were 
used to assess if CLIMB PPMS patients were different from the general clinic PPMS 
population. 
Time to EDSS=3 from disease onset (Phase 1), EDSS=6 from EDSS=3 (Phase 
2), and EDSS=6 from disease onset was estimated in each group using survival 
analysis techniques appropriate for interval censored data,(29) because some patients 
reached the disability landmark prior to entry and others did not reach the disability 
landmark at the last visit. PPMS patients were compared to the ROMS patients using an 
extension of the log-rank test appropriate for interval censored data.(30) Age at each 
EDSS landmark was also estimated using the same interval censored technique. For all 
of these analyses, the first EDSS=3 or EDSS=6 was used to calculate the times; future 
reversions were ignored as likely temporary improvement. In line with prior studies (6, 
24), time from onset to EDSS=4 and EDSS=7 were also estimated using a similar 
approach. 
In addition to the times to disability landmarks, the rate of sustained progression 
among PPMS patients was estimated. The same survival analysis was also conducted 
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on subgroups with baseline EDSS <5.5 and EDSS 5.5 at first visit. Subsequently, 
sample size calculations were made for hypothetical PPMS trials powered at 80% and 
alpha=0.05, with the outcome being a decrease of 30%, 50%, or 70% in the proportion 
of patients with sustained progression at one, two or three years. The power calculation 
used Freedman’s method and considered people who did not have sustained 
progression at the end of the trial as administratively censored. All statistical analysis 
was completed in the statistical package R (www.r-project.org) with the interval library 
(31) and the sample size calculations were made using the stpower routine in the 
statistical package STATA. 
 
Standard protocol approvals, registrations, and patient consents.  
Institutional Review Board approval was granted by Partners Human Research 
Committee. 
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Results:  
Demographic features  
Table 1 provides the demographics of the study groups. Only 4.5% (73/1614) of 
CLIMB MS patients had PPMS. This was similar to the proportion observed in our entire 
center (only 6% or 116/1933 of MS patients seen at the clinic between 2010 and 2012 
had PPMS). There was no significant difference in race and ethnicity between the 
PPMS and ROMS groups; however the proportion of males was significantly greater in 
the PP group (p<0.001). The age at disease onset and age at first visit were significantly 
higher in the PP group (p<0.001 for each comparison). Clinical disability at first visit, 
evaluated by the EDSS, was significantly greater in the PP group compared with the RO 
group (p<0.0001). Notably, a high proportion (78.1%) of the PP group was treated with 
immunomodulatory therapy during their disease course.   
Table 2 compares the demographic characteristics of the CLIMB and non-CLIMB 
PPMS patients. The MSSS was lower in CLIMB patients compared to non-CLIMB 
patients showing that CLIMB patients were slightly less disabled on average. No other 
significant differences between the groups were observed on any of the demographic or 
clinical variables.  
 
Symptom onset features 
First symptoms and their lesion localization were compared between PP and RO 
patients (Table 3).  Motor symptoms at onset were significantly more common in PP 
patients (p<0.001), while sensory and visual symptoms at disease onset were 
significantly more likely in RO patients (sensory: p<0.001, visual: p<0.001). The chance 
of first symptoms affecting coordination, bowel/bladder control, fatigue, or cognition was 
similar between both groups (p>0.05 for all). Comparison of first symptom lesion 
localization revealed a higher proportion of PP patients with spinal cord location 
(p<0.001). RO patients appeared to have a greater chance of optic nerve (p<0.001) or 
brainstem/cerebellum (p=0.01) first symptom lesion localization (Table 3). 
 
Time to EDSS milestones 
The time between EDSS landmarks for both PPMS and ROMS is shown in 
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Figure 1. Median time for progression to EDSS=3 was 2.8 years for the PP group and 
15.4 years in the RO group (p<0.001; Figure 1). Further analysis revealed that the 
median time from EDSS=3 to EDSS=6 was 4.8 years for the PP group and 10.7 years 
for the RO group (p<0.001; Figure 1). Finally, PPMS was associated with a shorter time 
to EDSS=6 (11.7 years) from onset compared with RO (32.2 years; p<0.001; Figure 1).  
The time to first EDSS=4 and first EDSS=7 were also significantly different between the 
two groups (p<0.001, Figure 2). Age at first EDSS=3 and EDSS=6 was older in the 
PPMS group compared to the ROMS group (Figure 3).   
 
Sustained Progression 
Time to sustained progression in the PPMS group was analyzed, and the 
Kaplan-Meir curve is shown in Figure 4. The median time to sustained progression was 
4.85 years (95% confidence interval (CI) 2.89-8.35) for all PPMS patients. There was a 
statistically significant difference between the PPMS and ROMS groups in terms of the 
hazard of sustained progression (estimated hazard ratio=2.33; 95% CI: 1.70-3.21; 
p<0.001), and the difference between ROMS and PPMS remained after controlling for 
age. When stratified based on baseline EDSS, the median time to sustained 
progression was 4.60 years for patients with EDSS score <5.5 at first visit and 4.85 
years for patients with EDSS score 5.5 at first visit.  
Given the distribution of time to sustained progression in PPMS patients, sample 
size calculations for future trials in PPMS patients are reported in Table 4. Three levels 
of treatment effect were estimated for trial durations of one, two, or three years. As 
expected, the sample size decreased as the length of trial increased and/or the 
treatment effect increased. 
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Discussion: 
PPMS is an understudied subtype of MS; however, it paradoxically has a more 
aggressive clinical course than ROMS. There are currently no approved therapies for 
PPMS, and none which have shown significant efficacy in slowing disease 
progression.(9, 10) This has been in part due to the limited knowledge of the disease 
mechanisms underlying progressive MS as well as the limited understanding of 
parameters for clinical trials to test agents.  
Here, we describe the demographic and clinical characteristics of our CLIMB 
PPMS patients, which are similar to previous cohorts and are a representative sample 
of PPMS patients seen at our clinic. Studies such as ours will, in aggregate, help in 
identifying clinical trial outcome measures and sample sizes to conduct such studies. 
Our sample adds to the limited number of cohort studies conducted in the modern 
diagnostic era.(8, 21, 32) In contrast, there are currently at least five clinical trials 
targeting PPMS patients listed on clinicatrials.gov at the time of this Scholarly Project 
Report preparation. The sample size estimates listed in Table 4, based on our 
observations, may provide guidance for the conduct of clinical trials for this underserved 
group of MS patients.  
Only 5% of patients in our sample were diagnosed with PPMS, which is lower 
than reported in Lyon, France (15.3%)(6, 24), Renne, France (21.7%)(25), British 
Columbia, Canada (10-12.4%)(21, 22), London, Ontario (19.7%)(33), Lorraine, France 
(8.8%)(34), South Wales Valley, UK (11.0%)(8), and Calgary, Canada (10.3%)(32). 
However, our PPMS patients are well defined by modern diagnostic criteria and PRMS 
patients were excluded, unlike previous studies.  
Our PPMS cohort had a male:female ratio of 1.09:1, similar to previous studies 
(1:1.3 (6, 33, 35, 36), 1:1.4(25), 1:1.13(21, 22), 1:1.12 (32), 1:1.1(8)). Mean age at onset 
(44.4 years) was higher than past reports (38.5-43.9 years).(6, 8, 21, 22, 25, 33) This 
may reflect problems with identifying true onset based on patient recall or population 
and geographical differences. As expected, both percentage male and onset age were 
significantly higher in the CLIMB PPMS patients compared to ROMS patients. 
Despite the difficulty in ascertaining the true onset in PPMS, most studies agree 
with our findings of preponderance for motor symptoms at onset in PPMS versus RO 
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individuals and the greater proportion of RO patients with sensory or visual symptoms, 
including optic neuritis, at onset.(6, 8, 21, 22, 25, 33, 35, 36) Like other cohorts, this 
PPMS cohort exhibited a small fraction of patients with brainstem/cerebellar localization 
of first symptom.(6, 8, 21, 36) Importantly, a significantly greater proportion of PP versus 
RO had initial symptom localization in the spinal cord.(13) 
Understanding progression of disability in modern PPMS patient populations is 
instrumental in designing successful trials. In this study, the median time to EDSS=6 
was similar to more recent reports regarding the natural history of PPMS versus 
historical cohorts. Specifically, the median time in the CLIMB PPMS group was 12 
years, which is similar to the times observed in recent cohorts (10.0 years in Renne(25), 
14 years in British Columbia(21), and 9.6 years in Wales(8)), but was  longer than 
historical cohorts that showed a median time to EDSS=6 of less than 9 years (6.0 years 
in Goteborg, Sweden(37), 7.1 years in Lyon(6, 24), and ~8.5 years in London, 
Ontario(33)). These data suggest slower disability accumulation in more recent cohorts, 
which may be a result of more modern diagnostic criteria, including MRI, allowing for 
earlier diagnosis or other changes in clinical care of patients over time.  
Our results do not support the recently proposed two-stage model of MS 
disability progression, with progression through Phase 1 being highly variable and 
progression through Phase 2 being largely consistent regardless of Phase 1 length. In 
this model, disability accumulation is influenced by focal inflammatory lesions in Phase 
1 and independent of focal inflammatory lesions during Phase 2.(6, 24, 25) As in other 
studies (6, 24, 25), our PP population had a significantly faster rate of progression from 
onset through EDSS=3 of disease compared to the RO group (p<0.001). Unlike prior 
studies, this cohort of PP patients progressed from EDSS=3 to EDSS=6 significantly 
faster than RO patients (p<0.001). Leray et al. previously reported significantly faster 
Phase 2 progression in progressive-onset patients as well, but the absolute difference 
of 0.8 years may not be clinically significant.(25) The CLIMB cohort had a greater 
absolute difference in Phase 2 progression rate (5.5 years), which we believe is 
clinically significant. Our data suggest that time through Phase 2 may not be so 
consistent among MS subtypes, implying that the two-stage disability progression model 
for MS may not apply to all subtypes of MS. However, the difference we note in Phase 2 
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progression compared to other reports may also be secondary to a better-performing 
modern ROMS cohort or the effect of disease modifying therapy as part of current 
standard of care. 
We have more confidence in our data for Phase 2 progression because many 
patients are seen in the clinic during this time, while Phase 1 involves symptoms at 
onset, which are difficult to ascertain and subject to more biases. A unique two-stage 
disability progression model may exist for PP and ROMS, with long-term progression of 
irreversible disability modified by early use of disease modifying therapies, underscoring 
the possibility of fundamental biological differences in disease.  
Koch et al. corroborated our finding that the proposed two-stage disability model 
does not apply in PPMS. In the original French ROMS cohorts, certain factors 
differentially influenced progression in the two phases- Phase 1 progression was 
associated with age at onset and sex while the same factors had no effect on Phase 2 
disability accrual.(24, 25) However, in the Calgary, Canada PPMS cohort, progression 
throughout Phase 1 and Phase 2 was affected by the same factor, age at disease 
onset.(32) PPMS does not appear to be defined by two independent phases 
demarcated by the EDSS landmarks of EDSS=3 or =4 and EDSS=6. 
Time to sustained progression in the CLIMB PPMS cohort (median time 4.85 
years) differed from more historical studies. In the study by Weinshenker et al., time to 
sustained progression using a compatible definition was, by extrapolation, ~2.5 
years.(38) More recently, Cottrell et al. presented median times to sustained 
progression stratified by baseline EDSS, ranging from 0.6 to 11.5 years.(39) Similar to 
other studies, progression was faster in the CLIMB PPMS cohort than the RO patients. 
Evaluation of time to sustained progression is particularly useful for design of clinical 
trials because it provides a shorter-term outcome measurement for therapeutic 
effectiveness.  
The canonical paper that describes sample size calculations for PPMS clinical 
trials is by Cottrell et al., based on natural history data from the London, Ontario PPMS 
cohort (PPMS onset between 1928-1982).(39) However, recent clinical trials highlight 
the need for updated information on PPMS progression rates and measurements of 
sustained disease progression for trial design. 
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Harding et al. recently sought to inform PPMS trial design by generating power 
estimates, based on the South Wales Valleys PPMS cohort natural history, for 
theoretical trials using EDSS progression as the outcome.(8) However, sustained 
progression on the EDSS is a more appropriate outcome measure for PPMS trials to 
evaluate the effect of interventions on disability accumulation. Power estimates from 
Harding et al. are for potential trials in which all participants share a baseline EDSS 
score.(8) Such an approach would be very difficult given the low prevalence of PPMS 
and difficulty in establishing a diagnosis and would likely require more patients than a 
population-based approach. A population-based design approach also allows greater 
generalizability of trial findings. 
Our data enable sample size calculations for PPMS trials in a modern patient 
cohort. Given the CLIMB PPMS progression rates, we estimated sample sizes for future 
trials and showed that larger studies may be necessary to observe treatment effects 
using the clinical outcome measures studied (Table 4).   
The CLIMB PPMS cohort reflects a modern patient sample managed with current 
standard of care. The proportions of patients with sustained progression in one, two, 
and three years is similar between the CLIMB PPMS group and the placebo control 
PPMS group in the halted glatiramer acetate trial (CLIMB: 0.183, 0.27, 0.394; GA trial: 
~0.20, ~0.32, ~0.48), suggesting that our patient data may be generalizable to the 
modern PPMS population and can provide new insights for clinical trial design. The rate 
of progression in CLIMB RRMS group has been described in detail in a previous 
publication.(40) 
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Limitations: 
There are some limitations to our study. In addition to referral bias to our center, 
not all patients elected to participate in the CLIMB study, resulting in a smaller sample 
size of PPMS patients. However, the 73 PPMS CLIMB patients included in this study 
are comparable to the PPMS patients who are not enrolled in CLIMB (Table 2) and 
demographic characteristics of the CLIMB PPMS patients are similar to previous 
studies. Another limitation in this and other PPMS studies is the challenge in making an 
accurate diagnosis of PPMS, often resulting in a delay between first symptoms and the 
first study visit (9.4 years in this study) that may affect the patient’s recall of disease 
onset. Additionally, since patients with PPMS often had substantial disability at the first 
CLIMB observation, our sample provided limited information regarding the exact 
disease duration at which subjects first reached EDSS=3 or =4. However, the interval-
censored model used allows for inclusion of these patients in analyses of progression. 
Future studies that follow PPMS subjects from the initial symptom will be required to 
estimate the exact survival curve with more precision.   
A limitation to the applicability of our findings, as in most natural history studies, 
is the use of EDSS as a marker of disability and disease progression. The EDSS scale 
is prone to inter- and intrarater variability.(41, 42) However, EDSS change currently 
remains the standard outcome measurement for clinical trials. Recent work using the 
CLIMB study has focused on alternative approaches for the analysis of progression 
data and the implications of this in terms of study design(43), but these alternative 
approaches are not commonly used in trials. Based on this previous work, we anticipate 
that the sample size requirements for trials using alternative outcomes will be reduced, 
but the amount of the reduction will depend on the analysis approach and the 
magnitude of the treatment effect.   
 We did not control for use of disease-modifying therapies in analyses of disease 
progression. This produces a clearer picture of disease natural history given the current 
standard of care and is particularly appropriate for studying PPMS because there is no 
proven disease-modifying therapy for PPMS. Furthermore, the efficacy of disease-
modifying therapy on long-term progression of irreversible disability in ROMS is not well 
known. 
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Conclusions: 
PPMS is an understudied population with no approved therapies. In light of 
recent clinical trials that failed due to controls progressing slower than predicted, there 
is a need for better assessment of PPMS natural history in the modern era to inform 
appropriate trial design. In this study, CLIMB PPMS patients were found to have similar 
demographic characteristics to previous cohorts and are a representative sample of 
PPMS patients seen at the Partners MS Center (Boston, MA). The time to EDSS 
landmarks in this study are longer than previously reported, but the difference between 
ROMS and PPMS remained highly significant and more importantly clinically 
meaningful. The time from EDSS=3 to EDSS=6, termed Phase 2 in previous studies, 
was found to be significantly different in PPMS compared to ROMS, which contradicts 
previous findings of similar time through this phase of disease. As such our data does 
not support the application of the proposed two-stage model of MS disability 
progression, based on progression to EDDS=3 and EDSS=6, in PPMS. Finally, the time 
to sustained progression showed that disease progression occurs at a slower rate in our 
sample than previously reported. Given this slower rate of progression, sample size 
estimates for future trials were estimated and showed that larger studies may be 
necessary to observe treatment effects using the clinical outcome measures studied. 
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Future Directions: 
 Future large single center and multicenter studies should assess the natural 
history of PPMS in the era of disease-modifying therapeutics in order to optimize the 
design of clinical trials in PPMS. They should validate and expand the small body of 
literature providing sample size and power estimates for future PPMS clinical trials. 
Ideally these estimates will be based on population-based PPMS cohorts and the 
outcome of choice, in line with current standards, will be sustained disease progression 
based on the EDSS. Such data is essential to designing successful trials that will 
hopefully yield therapeutics that slow PPMS disease progression.  
 While EDSS progression is the current outcome standard for trials, the EDSS 
scale is not ordinal and staying time at higher EDSS levels is significantly longer.(2, 8, 
33) It is also prone to inter- and intrarater variability.(41, 42) Alternative outcome 
measures may be more helpful in following disease evolution over the short term. 
Furthermore, PPMS therapeutic trials based on alternative outcomes may require fewer 
subjects and less time. As such, future studies must focus on validating alternative 
measures of MS progression. 
Finally, knowledge of prognostic factors is helpful in formulating treatment plans 
and providing care to PPMS patients. Several studies, with both retrospective and 
prospective design, have surveyed demographic and clinical variables as predictors of 
EDSS disability progression but findings have largely been inconsistent.(44) The most 
well-established prognostic factor for PPMS is age at disease onset. Findings from large 
PPMS cohorts in British Columbia, Canada(32), South Wales Valleys, UK(8), and 
Calgary, Canada(21) indicate that younger onset is associated with slower progression. 
Still, a study from Germany designed to validate reported prognostic factors did not find 
any variables predictive of PPMS disease progression.(44) It is clear that larger, 
multicenter studies are needed to assess the influence of demographic and clinical 
variables on PPMS disability progression. Furthermore, these studies should seek to 
evaluate the influence of environmental factors and biomarkers, such as vitamin D and 
immune markers, on PPMS disease course.  
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Tables and Figures: 
 
Table 1: Demographic characteristics of the patients 
 PP RO p Value 
N 73 1541 - 
Male, % 52.1 25.7 <0.001* 
White/Caucasian % 93.2 91.4† 1* 
Hispanic/Latino % 1.4 3.6 ‡ 0.51* 
Age at onset, mean(SD)  44.4 (9.6) 32.7 (9.9) <0.0001#
Time to first visit, mean(SD) 9.4 (7.4) 7.6 (8.7) 0.042# 
EDSS at first visit, mean(SD) 4.1 (1.9) 1.9 (1.7) <0.0001#
Ever treated, % 78.1 91.4 0.0006* 
   *Fisher’s exact test 
    #Wilcoxon rank sum test 
    †28 patients had unknown or unreported race and did not contribute to analysis 
    ‡22 patients had unknown or unreported ethnicity and did not contribute to analysis 
    PP: primary progressive multiple sclerosis 
    RO: relapsing-onset multiple sclerosis 
    EDSS: Expanded Disability Status Scale 
 
 
 
 
 
Table 2: Demographic characteristics of CLIMB PPMS patients compared to non-
CLIMB PPMS patients 
 CLIMB non-CLIMB p Value 
N 73 116 - 
Male, % 52.1 44.8 0.37* 
White/Caucasian % 93.2 88.7 0.44* 
Hispanic/Latino % 1.4 1.9 1* 
Age at onset, mean (SD)  44.4 (9.6) 43.8 (11.2) 0.78#
Age at last visit, mean (SD) 60.4 (7.9) 57.8 (10.5) 0.17# 
EDSS at last visit, mean 
(SD) 
5.1 (2.2) 5.7 (2.2) 0.16# 
Disease duration from first 
symptom at last visit, 
mean(SD) 
15.4 (8.5)  13.5 (8.6) 0.13# 
MSSS at last visit, mean 
(SD) 
5.9 (2.6) 6.7 (2.5)  0.01# 
   *Fisher’s exact test 
    #Wilcoxon rank sum test 
   EDSS: Expanded Disability Status Scale 
   MSSS: Multiple Sclerosis Severity Score  
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Table 3: Clinical Characteristics of first symptoms 
 PP RO p Value 
First symptom, n(%)    
     Visual 1 (1.4) 400 (26.0) <0.001 
     Motor 55 (75.3) 325 (21.1) <0.001 
     Sensory 16 (21.9) 805 (52.2) <0.001 
     Coordination 6 (8.2) 150 (9.7) 0.84 
     Bowel/Bladder 5 (6.8) 46 (3.0) 0.08 
     Fatigue 1 (1.4) 66 (4.3) 0.36 
     Cognitive 0 (0) 33 (2.1) 0.40 
     Encephalopathy 0 (0) 1 (0.1) 1 
     Other 1 (1.4) 136 (8.8) 0.02 
     None of the above 3 139  
First symptom location, n(%)    
     Optic nerve 0 (0) 342 (22.2) <0.001 
     Brainstem/cerebellum 8 (11.0) 368 (23.9) 0.01 
     Cerebrum 4 (5.5) 201 (13.0) 0.07 
     Spinal Cord 43 (58.9) 613 (39.8) 0.001 
     Not Defined 24 (32.9) 135 (8.8) <0.001 
     None of the above 1 139  
PP: primary progressive multiple sclerosis 
RO: relapsing-onset multiple sclerosis 
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Figure 1: Estimated survival curves for time through Phase 1, through Phase 2, 
and onset to EDSS=6 
 
Dashed line: primary progressive MS, Solid line: relapsing-onset MS. Top left: Time from 
disease onset to first EDSS=3, Top right: Time from disease onset to first EDSS=6, 
Bottom left: Time from first EDSS=3 to first EDSS=6. Grey highlighted regions represent 
sections of the curve where there is uncertainty regarding the exact survival due to the 
interval-censored nature of the data. 
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Figure 2: Time from disease onset until first EDSS=4 and first EDSS=7 
 
 
Dashed line: primary progressive MS, Solid line: relapsing-onset MS. Left: Time from 
disease onset to first EDSS=4, Right: Time from disease onset to first EDSS=7. Grey 
highlighted regions represent sections of the curve where there is uncertainty regarding 
the exact survival due to the interval censored nature of the data.  Estimated median time 
to first EDSS=4 in PPMS was 8.7 years, and estimated median time to first EDSS=4 in 
ROMS was 29.0.  Estimated median time to first EDSS=7 in PPMS was 41.7, and the 
estimated median time to first EDSS=7 in ROMS could not be estimated. 
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Figure 3: Age at first EDSS=3 and first EDSS=6 
 
 
Dashed line: primary progressive MS, Solid line: relapsing-onset MS. Left: Age at first 
EDSS=3, Right: Age at first EDSS=6. Grey highlighted regions represent sections of the 
curve where there is uncertainty regarding the exact survival due to the interval censored 
nature of the data.  Estimated median age at first EDSS=3 in PPMS was 44.3 years, and 
estimated median age at first EDSS=3 in ROMS was 50.8.  Estimated median age at first 
EDSS=6 in PPMS was 56.6, and the estimated median age at first EDSS=6 in ROMS 
was 69.2. 
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Figure 4: Kaplan-Meir curve showing time to sustained progression of disease 
 
Top left: Time to sustained progression for all PPMS patients, Top right: Time to sustained 
progression for PPMS with baseline EDSS < 5.5, Bottom left: Time to sustained 
progression for PPMS with baseline EDSS >= 5.5 
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Table 4: Kaplan-Meier estimates of time to sustained progression 
Study 
duration 
(Years) 
Estimated proportion 
with sustained 
progression in standard 
of care group 
Hypothesized 
proportion with 
sustained 
progression in 
treatment group 
Proportion 
change with 
sustained 
progression in 
treatment group 
Sample 
size for 
80% 
power 
1 0.183 0.128 30% 1368 
1 0.183 0.092 50% 446 
1 0.183 0.055 70% 210 
2 0.27 0.189 30% 850 
2 0.27 0.135 50% 286 
2 0.27 0.081 70% 136 
3 0.394 0.276 30% 504 
3 0.394 0.197 50% 174 
3 0.394 0.118 70% 86 
Note: Sample size calculations are for both groups assuming equal allocation in the two 
treatment arms.
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Appendix A: 
 
Kurtzke Expanded Disability Status Scale (EDSS) (15) 
 
EDSS 
Score 
Clinical Characteristics 
0 Normal neurological exam (all grade 0 in Functional Systems (FS); 
cerebral grade 1 acceptable). 
1 No disability, minimal signs in one FS (i.e., one grade 1 excluding 
cerebral grade 1). 
1.5 No disability, minimal signs in more than one FS (more than one grade 
1 excluding cerebral grade 1). 
2 Minimal disability in one FS (one FS grade 2, others 0 or 1). 
2.5 Minimal disability in two FS (two FS grade 2, others 0 or 1). 
3 Moderate disability in one FS (one FS grade 3, others 0 or 1), or mild 
disability in three or four FS (three to four FS grade 2, others 0 or 1). 
3.5 Moderate disability in one FS (grade 3) and one or two FS grade 2; or 
two FS grade 3 with others 0 or 1; or five FS grade 2 with others 0 or 1.
4 Fully ambulatory for some 500m without aid or rest and up and able to 
carry out full daily activities, but with relatively severe disability in one 
FS (one grade 4, others grade 0 or 1), or combination of lesser grades 
that exceeds the limits of prior stages. 
4.5 Fully ambulatory without aid, up and about much of the day, able to work 
a full day but may otherwise have some limitation in full activity or require 
minimal assistance; characterized by relatively severe disability, usually 
consisting of one FS grade 4 (others 0 or 1) or combinations of lesser 
grades exceeding limits of prior steps. Able to walk without aid or rest 
for some 300 meters (975 ft). 
5 Ambulatory without aid or rest for about 200 meters (650 feet); disability 
severe enough to impair full daily activities (e.g., to work full day without 
special provisions). Usual FS equivalents are one grade 5 alone (others 
0 or 1) or combinations of lesser grades usually exceeding 
specifications for step 4.0 
5.5 Ambulatory without aid or rest for about 100 meters (325 ft); disability 
severe enough to impair ability to work part-time without special 
provisions. Usual FS equivalents are one grade 5 alone (others 0 or 1) 
or combinations of lesser grades usually exceeding specifications for 
step 4.0 
6 Intermittent or constant unilateral assistance (cane, crutch, brace) 
required to walk about 100 meters (325 ft) with or without resting. Usual 
FS equivalents are combinations with more than two FS grade 3+ 
6.5 Constant bilateral assistance (canes, crutches, braces) required to walk 
about 20 meters (65 ft). Usual FS equivalents are combinations with 
more than two FS grade 3+ 
7 Unable to walk beyond about 5 meters (16 ft) even with aid, essentially 
restricted to wheelchair; wheels self in standard wheelchair for a full day 
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(12 hours) and transfers alone. Usual FS equivalents are combinations 
with more than one FS grade 4+ or very rarely pyramidal grade 5 alone.
7.5 Unable to take more than a few steps; restricted to wheelchair, wheels 
self but cannot carry on in standard wheelchair for full day and may need 
aid in transfers; may require motorized wheelchair. Usual FS 
equivalents are combinations with more than one FS grade 4+ 
8 Essentially restricted to bed or chair or perambulated in wheelchair, but 
may be out of bed itself much of the day. Retains many self-care 
functions and generally has effective use of arms. Usual FS equivalents 
are combinations, generally grade 4+ in several systems. 
8.5 Essentially restricted to bed for much of the day. Retains some self-care 
functions and has some effective use of arm(s). Usual FS equivalents 
are combinations, generally grade 4+ in several systems. 
9  Helpless bed patient who can still communicate and eat. Usual FS 
equivalents are combinations, mostly grade 4. 
9.5 Totally helpless bed patient who is unable to communicate effectively or 
eat/swallow. Usual FS equivalents are combinations, almost all grade 
4+ 
10 Death due to MS.  
 
